Kidney Res Clin Pract > Volume 42(3); 2023 > Article |
|
Characteristic | All patients (n = 1,271) | Functioning graft (n = 1,056) | Graft loss (n = 215) | p-valuea | Hazard ratio | p-valueb |
---|---|---|---|---|---|---|
Donor | ||||||
MYH9 SNP | 317 (24.0) | 264 (25.0) | 53 (24.8) | 0.97 | 0.98 | |
CC | 687 (54.1) | 572 (54.2) | 115 (53.7) | |||
CA | 265 (20.9) | 219 (20.8) | 46 (21.5) | |||
AA | ||||||
Age (yr) | 44.4 ± 14.4 | 44.1 ± 14.6 | 46.1 ± 13.4 | 0.04* | 1.02 | <0.001* |
Male sex | 645 (50.7) | 535 (50.7) | 110 (51.2) | 0.89 | 0.96 | |
Blood group | ||||||
Type O | 642 (50.5) | 541 (51.3) | 101 (47.2) | 0.03* | 0.39 | 0.004* |
Type A | 502 (39.5) | 414 (39.3) | 88 (41.1) | 0.42 | 0.01* | |
Type B | 97 (7.6) | 82 (7.8) | 15 (7.0) | 0.36 | 0.01* | |
Type AB | 27 (2.1) | 17 (1.6) | 10 (4.7) | Reference | 0.04* | |
Donor type | ||||||
Living | 282 (22.2) | 257 (24.3) | 25 (11.6) | <0.001* | Reference | 0.002* |
Brain death | 787 (61.9) | 642 (60.8) | 145 (67.4) | 1.94 | ||
Circulatory death | 202 (15.9) | 157 (14.9) | 45 (20.9) | |||
Recipient | ||||||
MYH9 SNP | 326 (25.7) | 270 (25.6) | 56 (26.2) | 0.15 | 0.31 | |
CC | 635 (50.0) | 539 (51.1) | 96 (44.9) | |||
CA | 308 (24.3) | 246 (23.3) | 62 (29.0) | |||
AA | ||||||
Age (yr) | 47.9 ± 13.5 | 48.5 ± 13.4 | 45.0 ± 13.2 | <0.001* | 0.99 | 0.03* |
Male sex | 739 (58.1) | 607 (57.5) | 132 (61.4) | 0.29 | 0.21 | |
Primary kidney disease | ||||||
Glomerulonephritis | 340 (26.8) | 271 (25.6) | 69 (32.2) | 0.28 | 0.45 | |
Polycystic disease | 208 (16.4) | 188 (17.8) | 20 (9.3) | |||
Vascular disease | 145 (11.4) | 123 (11.6) | 22 (10.3) | |||
Pyelonephritis | 148 (11.6) | 120 (11.4) | 28 (13.1) | |||
Diabetes | 51 (4.0) | 44 (4.2) | 7 (3.3) | |||
Idiopathic | 168 (13.2) | 134 (12.7) | 34 (15.9) | |||
Others | 211 (16.6) | 177 (16.7) | 34 (15.9) | |||
Blood group | ||||||
Type O | 567 (44.6) | 474 (44.9) | 93 (43.3) | 0.004* | 0.46 | 0.002* |
Type A | 536 (42.2) | 448 (42.4) | 88 (40.9) | 0.46 | 0.002* | |
Type B | 113 (8.9) | 98 (9.3) | 15 (7.0) | 0.35 | 0.002* | |
Type AB | 55 (4.3) | 36 (3.4) | 19 (8.8) | Reference | 0.008* | |
Dialysis vintage (wk) | 172 (91–263) | 174 (87–261) | 168 (109–270) | 0.15 | 0.10 | |
Highest PRA (%) | 10.1 ± 23.6 | 10.0 ± 23.3 | 10.9 ± 25.0 | 0.60 | 0.75 | |
Antihypertensives | 1,131 (89.0) | 945 (89.5) | 186 (86.5) | 0.20 | 0.36 | |
Induction immunosuppression | ||||||
Anti-CD3 MoAb | 19 (1.5) | 14 (1.3) | 5 (2.3) | 0.27 | 0.51 | |
ATG | 103 (8.1) | 79 (7.5) | 24 (11.2) | 0.07 | 0.14 | |
Interleukin-2 RA | 199 (15.7) | 163 (15.4) | 36 (16.7) | 0.63 | 0.12 | |
Maintenance immunosuppression | ||||||
Azathioprine | 72 (5.7) | 53 (5.0) | 19 (8.8) | 0.03* | 0.29 | |
Corticosteroids | 1,201 (94.5) | 1,002 (94.9) | 199 (92.6) | 0.17 | 0.51 | 0.01* |
Cyclosporin | 1,085 (85.4) | 911 (86.3) | 174 (80.9) | 0.04* | 0.66 | 0.02* |
Mycophenolic acid | 907 (71.4) | 775 (73.4) | 132 (61.4) | <0.001* | 0.06 | |
Sirolimus | 38 (3.0) | 33 (3.1) | 5 (2.3) | 0.53 | 0.54 | |
Tacrolimus | 97 (7.6) | 77 (7.3) | 20 (9.3) | 0.31 | 0.39 | |
Transplantation | ||||||
CIT (hr) | 17.7 (10.9–23.0) | 17.0 (8.6–23.0) | 20.0 (15.3–25.0) | <0.001* | 1.03 | 0.001* |
WIT (min) | 37.0 (31–45) | 37.0 (30–45) | 38.0 (32–45) | 0.12 | 1.02 | 0.003* |
Total HLA mismatches | 2 (1–3) | 2 (1–3) | 2 (1–3) | 0.48 | 0.11 | |
DGF | 415 (32.7) | 289 (27.4) | 126 (58.6) | <0.001* | 3.79 | <0.001* |
Data are expressed as number (%), mean ± standard deviation, or median (interquartile range).
ATG, anti-thymocyte globulin; CD3, cluster of differentiation 3; CIT, cold ischemia time; DGF, delayed graft function; MYH9, myosin heavy chain 9 gene; HLA, human leukocyte antigen; PRA, panel-reactive antibody; RA, receptor antagonist; SNP, single-nucleotide polymorphism; WIT, warm ischemia time.
Multivariable logistic regression was performed for delayed graft function after kidney transplantation. Only variables with a p-value of <0.05 in the univariable analysis were included. Donor age, donor sex, donor type, total HLA mismatches, dialysis vintage, and warm ischemia time were significant, whereas the MYH9 SNP (rs11089788) in the recipient, recipient age, and cold ischemia time were not.
CI, confidence interval; HLA, human leukocyte antigen; MYH9, myosin heavy chain 9 gene; SNP, single-nucleotide polymorphism.
Multivariable Cox regression was performed for biopsy-proven acute rejection after kidney transplantation. Only variables with a p < 0.05 in the univariable analysis were included. Recipient age, total HLA mismatches, delayed graft function, and recipient sex were significant, whereas the MYH9 polymorphism (rs11089788) in the recipient and warm ischemia time were not.
CI, confidence interval; HLA, human leukocyte antigen; MYH9, myosin heavy chain 9 gene; SNP, single-nucleotide polymorphism.
Characteristic | All patients (n = 1,271) | AA–AA pair (n = 80) | Other pairs (n = 1,187) | p-valuea |
---|---|---|---|---|
Donor | ||||
Age (yr) | 44.4 ± 14.4 | 46.8 ± 12.9 | 44.2 ± 14.5 | 0.12 |
Male sex | 645 (50.7) | 43 (53.8) | 601 (50.6) | 0.59 |
Blood group | ||||
Type O | 642 (50.5) | 40 (50.0) | 600 (50.7) | 0.93 |
Type A | 502 (39.5) | 32 (40.0) | 469 (39.6) | |
Type B | 97 (7.6) | 7 (8.8) | 89 (7.5) | |
Type AB | 27 (2.1) | 1 (1.3) | 26 (2.2) | |
Donor type | ||||
Living | 282 (22.2) | 30 (37.5) | 251 (21.1) | 0.001* |
Brain death | 787 (61.9) | 35 (43.8) | 749 (63.1) | |
Circulatory death | 202 (15.9) | 15 (18.8) | 187 (15.8) | |
Recipient | ||||
Age (yr) | 47.9 ± 13.5 | 48.1 ± 13.1 | 47.9 ± 13.5 | 0.91 |
Male sex | 739 (58.1) | 43 (53.8) | 694 (58.5) | 0.41 |
Blood group | ||||
Type O | 567 (44.6) | 31 (38.8) | 534 (45.0) | 0.38 |
Type A | 536 (42.2) | 34 (42.5) | 501 (42.2) | |
Type B | 113 (8.9) | 11 (13.8) | 101 (8.5) | |
Type AB | 55 (4.3) | 4 (5.0) | 51 (4.3) | |
Dialysis vintage (wk) | 172 (91–263) | 169 (74–267) | 173 (91–262) | 0.67 |
Highest PRA (%) | 10.1 ± 23.6 | 9.3 ± 23.2 | 10.2 ± 23.6 | 0.78 |
Induction immunosuppression | ||||
Anti-CD3 MoAb | 19 (1.5) | 1 (1.3) | 18 (1.5) | 0.85 |
ATG | 103 (8.1) | 6 (7.5) | 97 (8.2) | 0.83 |
Interleukin-2 RA | 199 (15.7) | 15 (18.8) | 184 (15.5) | 0.44 |
Maintenance immunosuppression | ||||
Azathioprine | 72 (5.7) | 5 (6.3) | 67 (5.6) | 0.82 |
Corticosteroids | 1,201 (94.5) | 78 (97.5) | 1,119 (94.3) | 0.22 |
Cyclosporin | 1,085 (85.4) | 69 (86.3) | 1,012 (85.3) | 0.81 |
Mycophenolic acid | 907 (71.4) | 56 (70.0) | 847 (71.4) | 0.80 |
Sirolimus | 38 (3.0) | 3 (3.8) | 35 (2.9) | 0.68 |
Tacrolimus | 97 (7.6) | 8 (10.0) | 89 (7.5) | 0.42 |
Transplantation | ||||
CIT (hr) | 17.7 (10.9–23.0) | 15.5 (2.8–20.0) | 18.0 (11.5–23.0) | 0.002* |
WIT (min) | 37.0 (31.0–45.0) | 36.5 (30.3–45.0) | 37.0 (31.0–45.0) | 0.90 |
Total HLA mismatches | 2 (1–3) | 3 (1–3) | 2 (1–3) | 0.004* |
DGF | 415 (32.7) | 33 (41.3) | 380 (32.0) | 0.09 |
Data are expressed as number (%), mean ± standard deviation, or median (interquartile range).
ATG, anti-thymocyte globulin; CD3, cluster of differentiation 3; CIT, cold ischemia time; DGF, delayed graft function; HLA, human leukocyte antigen; MoAb, monoclonal antibody; MYH9, myosin heavy chain 9 gene; PRA, panel-reactive antibody; RA, receptor antagonist; WIT, warm ischemia time.
Model |
MYH9 SNP (rs1800472) in donor-recipient pairs |
|
---|---|---|
Hazard ratioa (95% CI) | p-value | |
1 | 1.78 (1.13–2.79) | 0.01 |
2 | 1.90 (1.19–3.02) | 0.007 |
3 | 1.95 (1.24–3.08) | 0.004 |
4 | 1.91 (1.16–3.12) | 0.01 |
Model 1, crude model; model 2, adjusted for model 1 plus recipient characteristics (recipient age, recipient sex, recipient blood type, and dialysis vintage); model 3, adjusted for model 1 plus donor characteristics (donor age, donor sex, donor blood type, and donor origin); model 4: adjusted for model 1 plus transplant characteristics (cold and warm ischemia time, and the number of human leukocyte antigen-mismatches).
CI, confidence interval; MYH9, myosin heavy chain 9 gene; SNP, single-nucleotide polymorphism.
Multivariable Cox regression was performed for kidney graft survival. Only variables with a p < 0.05 in the univariable analysis were included. In the final model, the MYH9 SNP (rs11089788) in donor-recipient pairs, the occurrence of delayed graft function, recipient age, and donor age were significant, whereas recipient blood type, warm ischemia time, use of corticosteroids, cold ischemia time, donor type, use of cyclosporin A, and donor blood type were not.
CI, confidence interval; MYH9, myosin heavy chain 9 gene; SNP, single-nucleotide polymorphism; NA, not available.
Felix Poppelaars
https://orcid.org/0000-0002-5173-8078
Siawosh K. Eskandari
https://orcid.org/0000-0003-4867-4170
Jeffrey Damman
https://orcid.org/0000-0001-5997-7551
Marc A. Seelen
https://orcid.org/0000-0003-2240-4682
Bernardo Faria
https://orcid.org/0000-0001-9112-8920
Mariana Gaya da Costa
https://orcid.org/0000-0002-9201-5108
A case of Ramsay Hunt syndrome diagnosed after kidney transplantation2015 December;34(4)